Fludeoxyglucose F18 ([¹⁸F]FDG) Injection Analysis Helps Researchers to Control the Process of Drug Development

[¹⁸F]FDG) is a positron-emitting radiotracer employed in conjunction with positron emission tomography (PET) for diagnosing and monitoring various medical conditions. While standard imaging modalities like X-ray, computed tomography (CT), and magnetic resonance imaging (MRI) offer detailed visualization of healthy and diseased tissues, they may not capture diseases lacking structural abnormalities or in early stages. Functional imaging techniques, such as PET scans, complement structural modalities by visualizing blood flow and metabolic activities using radiotracers like [¹⁸F]FDG, which accumulates in tissues with high glucose demand, such as tumors and inflammatory cells. CD BioGlyco provides [¹⁸F]FDG analysis services, particularly for injections, ensuring accurate and reliable results for studying glucose metabolism. Moreover, we also provide other Pharmaceutical Analysis services based on our advanced platform.

Fig.1 The structure of [¹⁸F]FDG. (CD BioGlyco)

Our comprehensive [¹⁸F]FDG injection analysis service covers a range of critical tests. Our service includes the identification test, bacterial endotoxin test, pH test, residual solvent test, some purity test, and the radioactivity assay. With our expertise, we ensure accurate and reliable results, supporting clients in maintaining high-quality standards for [¹⁸F]FDG injections.

Here is our content of standard analysis

• The identification test (radionuclidic identity and radiochemical identity)
• Bacterial endotoxin test
• pH test
• Residual solvent test
• Radioactivity assay
• Radiochemical purity test
• Radionuclidic test
• Chemical test

Fig.2 The standard flowchart for testing the radiochemical, radionuclidic, and chemical purity of [¹⁸F]FDG. (CD BioGlyco)

Publication Data

Frequently Asked Questions

• Why [¹⁸F]FDG can be used to detect glucose metabolism rates in tissues?

Hexokinases initiate cellular glucose metabolism by converting glucose to glucose-6-phosphate. This phosphorylation traps glucose inside cells, as glucose-6-phosphate cannot diffuse out. [¹⁸F]FDG, a glucose analog with a radioactive 18-fluorine tracer, mimics glucose but lacks a hydroxyl group at the 2-C position. PET scans using [¹⁸F]FDG reveal abnormal glucose consumption, particularly in tumors with high glycolysis rates. The emitted positrons from fluorine-18 decay generate signals in PET cameras, enabling the detection of glucose metabolism rates in tissues.

• What is the recommended dosage for [¹⁸F]FDG injection in pharmaceutical research?

Radioactivity is measured in curies (Ci) or becquerels (Bq). The decay factor, calculated post-end-of-synthesis (EOS) based on fluorine-18's 110-minute half-life, determines the optimal dose for PET imaging. For adults, the recommended dose is 5–10 mCi (185–370 MBq), while pediatric patients receive 2.6 mCi (96.2 MBq). Pediatric dosing is independent of body size or weight.

Applications

• Our [¹⁸F]FDG injection analysis service can be used to confirm the correct compound, the absence of bacterial contamination, and optimal acidity/alkalinity for accurate and safe diagnostic use.
• Our [¹⁸F]FDG injection analysis service can be used to evaluate the composition, ensuring the presence of the intended radioactive compounds and overall chemical purity, critical for precise diagnostic imaging.
• Our [¹⁸F]FDG injection analysis service can be used to detect and quantify any residual solvents, contributing to the safety of patients by ensuring the absence of harmful substances.

At CD BioGlyco, our [¹⁸F]FDG injection analysis service covers a range of crucial tests to ensure the quality and safety of the product. This comprehensive service ensures the reliability of [¹⁸F]FDG injections, supporting pharmaceutical and research needs. For further information or to request a quote, please do not hesitate to contact us.